Valuation: Curis, Inc.

Market Cap 13.86M 12.11M 11.13M 10.38M 19.68M 1.32B 19.98M 134M 51.95M 649M 52.01M 50.9M 2.23B P/E 2026 *
-0.22x
P/E 2027 * -0.34x
Enterprise Value 13.86M 12.11M 11.13M 10.38M 19.68M 1.32B 19.98M 134M 51.95M 649M 52.01M 50.9M 2.23B EV / Sales 2026 *
7.92x
EV / Sales 2027 * 1.09x
Free-Float
91.97%
Yield 2026 *
-
Yield 2027 * -
1 day-17.89%
1 week+7.98%
Current month-33.61%
1 month-26.77%
3 months-36.97%
6 months-64.80%
Current year-64.89%
1 week 6.81
Extreme 6.81
11.4
1 month 3.61
Extreme 3.612
11.4
Current year 3.61
Extreme 3.612
24.2
1 year 3.61
Extreme 3.612
40.28
3 years 3.61
Extreme 3.612
360
5 years 3.61
Extreme 3.612
3,616
10 years 3.61
Extreme 3.612
7,440
Manager TitleAgeSince
Chief Executive Officer 59 2018-09-23
Director of Finance/CFO 54 2022-08-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 2003-10-31
Chairman 84 2017-05-15
Director/Board Member 71 2010-06-02
Date Insider Type Main position Quantity % Market Cap.
03-30Buy

Director

10,000 0.0728%
03-19Conversion

Chief Technology Officer

66,667 0.4854%
03-19Conversion

Director

26,667 0.1942%
Change 5-day change 1-year change 3-year change Capi.($)
-17.89%+7.98%-80.85%-97.89% 13.86M
+2.19%+8.75%+5.16%+11.05% 49.92B
+0.92%+3.93%+399.71%+604.02% 40.23B
+1.89%+8.32%+26.06%-6.27% 34.55B
+2.38%+6.35%+21.25%+55.45% 33.09B
+3.96%+10.67%+8.30%+37.95% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+135.37% 15.92B
+1.01%+2.76%+16.22%+24.00% 13.86B
+3.30%+0.76%+90.23%+93.88% 13.52B
Average +0.28%+12.08%+62.17%+95.29% 24.57B
Weighted average by Cap. +2.20%+6.54%+90.91%+136.78%

Financials

2026 *2027 *
Net sales 1.75M 1.53M 1.41M 1.31M 2.49M 167M 2.52M 16.88M 6.56M 81.9M 6.57M 6.43M 282M 12.75M 11.15M 10.24M 9.55M 18.11M 1.21B 18.38M 123M 47.8M 597M 47.86M 46.83M 2.06B
Net income -45.15M -39.47M -36.27M -33.81M -64.13M -4.3B -65.1M -435M -169M -2.11B -169M -166M -7.28B -35.44M -30.98M -28.47M -26.54M -50.34M -3.37B -51.1M -342M -133M -1.66B -133M -130M -5.72B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26-07-02 US$6.932 -17.89% 118,674
26-07-01 US$8.442 -19.15% 229,164
26-06-30 US$10.44 +18.12% 637,537
26-06-29 US$8.840 +37.69% 1,907,159
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
6.932USD
Average target price
280.00USD
Spread / Average Target
+3,939.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock